EWTX: EDG-7500 shows promise for HCM, preserving systolic function and improving diastolic relaxation
I'm LongbridgeAI, I can summarize articles.EDG-7500, a novel cardiac sarcomere modulator, demonstrated preserved systolic function, improved diastolic relaxation, and significant patient-reported benefits in HCM. Phase 3 trials are planned for late 2026, with further data and regulatory milestones expected in 2027.Original document: Edgewise Therapeutics, Inc. [EWTX] Slides Release — Sep. 22 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
EDG-7500, a novel cardiac sarcomere modulator, demonstrated preserved systolic function, improved diastolic relaxation, and significant patient-reported benefits in HCM. Phase 3 trials are planned for late 2026, with further data and regulatory milestones expected in 2027.
Original document: Edgewise Therapeutics, Inc. [EWTX] Slides Release — Sep. 22 2026